Table 1 Baseline clinical characteristics and risk factors of COVID-19 patients treated with either IVIG or with standard COVID-19 therapy
Feature | Control group | IVIG group | Statistics | p value |
|---|---|---|---|---|
Patient number, N (%) | 109 (59.6) | 74 (40.4) | ||
Male/female, N (%) | 63.45 | 45.29 | ||
Age years, mean (STD) | 63.28 (16.81) | 61.89 (13.38) | 0.62 | 0.536 |
Days interval from symptoms onset and therapy starting, days No | 7.14 | 7.08 | − 0.085 | 0.933 |
Vital signs on admission | ||||
T | 37.33 | 37.48 | 0.938 | 0.394 |
SO2 | 82.35 | 80.56 | − 0.864 | 0.389 |
BP | 129.63 | 127.20 | − 0.785 | 0.434 |
RR | 26.68 | 26.63 | − 0.022 | 0.983 |
PR | 95.06 | 96.94 | 0.647 | 0.518 |
Risk factors | ||||
Diabetes | 28 | 29 | 3.232 | 0.072 |
Hypertension | 43 | 35 | 0.965 | 0.326 |
Obesity | 5 | 5 | 0.105 | 0.746 |
Pregnancy | 2 | 0 | 0.192 | 0.661 |
Vasculitis | 0 | 0 | – | – |
Embolism | 0 | 1 | 0.041 | 0.840 |
Asthma | 3 | 2 | 0.000 | 1.000 |
Bronchiectasis | 1 | 2 | 0.124 | 1.000 |
Member link?? | 1 | 0 | 0.000 | 0.725 |
Chemotherapy | 0 | 0 | – | – |
Corticosteroid therapy | 0 | 0 | – | – |
Gout | 1 | 1 | 0.000 | 1.000 |
Hemodialysis | 4 | 3 | 0.000 | 1.000 |
Malignancy | 9 | 1 | 2.77 | 0.096 |
Stent | 5 | 5 | 0.120 | 0.729 |
Heart failure | 6 | 10 | 2.710 | 0.100 |
Kidney failure | 8 | 4 | 0.036 | 0.849 |
Liver failure | 3 | 1 | 0.012 | 0.914 |